ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Japanese stem cell treatment for Parkinson's set for US trials

Sumitomo Dainippon Pharma aims for commercial breakthrough in iPS therapies

Work is underway to use iPS cells -- cells reprogrammed to an embryonic state -- in regenerative treatments for incurable diseases.

OSAKA -- A Japanese drugmaker plans clinical trials in the U.S. of a regenerative treatment for Parkinson's disease that uses reprogrammed cells, Nikkei has learned.

Osaka-based Sumitomo Dainippon Pharma plans to begin the American trials in fiscal 2022. The goal is to produce a cell transplant treatment that improves the condition of patients with Parkinson's, rather than simply slowing the disease's progress.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more